financetom
Business
financetom
/
Business
/
UK's M&G gets approval for long-term asset fund
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UK's M&G gets approval for long-term asset fund
Mar 10, 2025 7:18 AM

March 10 - British insurer and asset manager M&G

said on Monday its private markets business had received

regulatory approval for its first long-term asset fund.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sabadell's board meets to analyse BBVA bid proposal, newspapers say
Sabadell's board meets to analyse BBVA bid proposal, newspapers say
May 6, 2024
MADRID (Reuters) - Spanish bank Sabadell's board will meet on Monday to discuss an all-share offer from bigger rival BBVA that was worth around 12 billion euros ($12.9 billion) when it was announced last week, newspapers including La Vanguardia said. Sabadell was not immediately available for comment. La Vanguardia said the meeting would start around noon (1000 GMT), without providing...
French carmakers target fourfold jump in EV sales by 2027
French carmakers target fourfold jump in EV sales by 2027
May 6, 2024
PARIS (Reuters) - France's car industry will aim to ramp up electric car sales fourfold by 2027 under a strategy agreement to be signed with the government on Monday, just as the president of China embarks on a state visit in the country. French President Emmanuel Macron has set a goal for the nation's carmakers to produce two million electric or...
Calliditas Therapeutics' Potential Head and Neck Cancer Treatment Meets Secondary Endpoints
Calliditas Therapeutics' Potential Head and Neck Cancer Treatment Meets Secondary Endpoints
May 6, 2024
04:56 AM EDT, 05/06/2024 (MT Newswires) -- Calliditas Therapeutics ( CALT ) said Monday that data from a phase 2 trial of its drug candidate setanaxib in combination with pembrolizumab in patients with head and neck cancer met its secondary endpoints, including progress-free survival and overall survival. The randomized, placebo-controlled, double-blind study of 55 patients with squamous cell carcinoma of...
Perficient's Q1 Adjusted Earnings, Revenue Decline; Agrees to be Acquired for $3 Billion
Perficient's Q1 Adjusted Earnings, Revenue Decline; Agrees to be Acquired for $3 Billion
May 6, 2024
05:09 AM EDT, 05/06/2024 (MT Newswires) -- Perficient (PRFT) reported Q1 adjusted earnings Sunday of $0.77 per diluted share, down from $1.04 a year earlier. Analysts polled by Capital IQ expected $0.80. Revenue for the quarter ended March 31 was $215.3 million, compared with $231.4 million a year earlier. Analysts surveyed by Capital IQ expected $216.5 million. In a separate...
Copyright 2023-2026 - www.financetom.com All Rights Reserved